Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Oncology NGS market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Oncology NGS market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
The Oncology NGS market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Oncology NGS products across developed and developing countries of the world.
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Oncology NGS products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Oncology NGS market.
To learn more about this report
Increasing research and development spending on Oncology NGS development has been the leading industry trend of Oncology NGS market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
To learn more about this report
| Report Attributes | Details |
| The market size value in 2021 | USD XX.XX Million |
| CAGR (2021 - 2028) | XX.XX % |
| The Revenue forecast in 2028 | USD XX.XX Million |
| Base year for estimation | 2021 |
| Historical data | 2018-2019 |
| Forecast period | 2022-2028 |
| Quantitative units |
|
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered | By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook | Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities, Other users |
| By Application Outlook | Diagnostics and Screening, Screening, Sporadic Cancer, Inherited Cancer, Companion Diagnostics, Other Diagnostics, Research Studies |
| Regional scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope | U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled | Illumina, Inc., Genotypic Technology Pvt. Ltd., Tecan Trading AG, SciGenom Labs Pvt. Ltd., Xcelris Labs Ltd., Eurofins Scientific, 4baseCare, MedGenome, Sayre Therapeutics, Redcliffe Lifesciences, Partek Inc., Bio-Rad Laboratories, Myriad Genetics, Hologic, Inc. (Gen-Probe Inc.), Perkin Elmer, IncVela Diagnostics, Premas Life Sciences Pvt Ltd (PLS) |
| Customization Available | Yes, the report can be tailored to meet your specific requirements. |
1 Methodology and Scope
1.1 Market segmentation & scope
1.2 Information Procurement
1.2.1 Purchased Database
1.2.2 Eternity’s Internal Database
1.2.3 Secondary sources & third-party perspectives
1.2.4 Primary Research
1.3 Information analysis
1.4 Market formulation & data visualization
1.5 Data validation & publishing
2 Executive Summary
3 Oncology NGS Market Variables, Trends & Scope
3.1 Market Dynamics
3.1.1 Market Driver Analysis
3.1.2 Market Restraints
3.1.3 Market Challenge Analysis
3.1.4 Market Opportunities
3.1.5 Micro & Macro Indicator
3.2 Impact of COVID-19 Pandemic on Global Oncology NGS Market
3.2.1 Overview of Changing Landscape
3.2.2 Pre-covid & Post-Covid Market Analysis
3.3 Market Attractiveness Analysis
3.4 Regulatory Scenario
3.5 Industry Trend Analysis- Historic and Future Trend Assessment
3.6 Merger & Acquisition
3.7 New System Launch/Approvals
3.8 Market Analysis Tools
3.8.1 Porter’s Five Forces
3.8.2 PEST Analysis
3.8.3 Value Chain Analysis
3.9 Key Company Ranking Analysis, 2020
4 Global Oncology NGS Market Analysis and Forecast, By Type
4.1 Overview & Definition
4.2 Key Trends
4.3 Global Oncology NGS Market Value (US$ Mn) Forecast, by Type (2019 – 2028)
4.2.1 Academic Research
4.2.2 Clinical Research
4.2.3 Hospitals & Clinics
4.2.4 Pharma & Biotech Entities
4.2.5 Other users
4.4 Type Comparison Matrix
4.5 Global Oncology NGS Market Attractiveness, By Type
5 Global Oncology NGS Market Analysis and Forecast, By Application
5.1 Overview & Definition
5.2 Key Trends
5.3 Global Oncology NGS Market Value (US$ Mn) Forecast, by Application (2019 – 2028)
5.3.1 Diagnostics and Screening
5.3.2 Screening
5.3.3 Sporadic Cancer
5.3.4 Inherited Cancer
5.3.5 Companion Diagnostics
5.3.6 Other Diagnostics
5.3.7 Research Studies
5.4 Application Comparison Matrix
5.5 Global Oncology NGS Market Attractiveness, by Application
6 Global Oncology NGS Market Analysis and Forecast, By Region
6.1 Overview & Definition
6.2 Key Trends
6.3 Global Oncology NGS Market Value (US$ Mn) Forecast, by Region (2019 – 2028)
6.4 North America
6.5 Europe
6.6 Asia Pacific
6.7 Latin America
6.8 Middle East & Africa
7 Global Oncology NGS Market Attractiveness, by Region
8 North America Oncology NGS Market Analysis and Forecast
8.1 Key Findings
8.2 North America Oncology NGS Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)
8.2.1 Academic Research
8.2.2 Clinical Research
8.2.3 Hospitals & Clinics
8.2.4 Pharma & Biotech Entities
8.2.5 Other users
8.3 North America Oncology NGS Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)
8.3.1 Diagnostics and Screening
8.3.2 Screening
8.3.3 Sporadic Cancer
8.3.4 Inherited Cancer
8.3.5 Companion Diagnostics
8.3.6 Other Diagnostics
8.3.7 Research Studies
8.4 North America Oncology NGS Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)
8.4.1 U.S.
8.4.2 Canada
8.4.3 Rest of North America
8.5 North America Oncology NGS Market Attractiveness Analysis
8.5.1 By Type
8.5.2 By Application
8.5.3 By Country
9 Europe Oncology NGS Market Analysis and Forecast
9.1 Key Findings
9.2 Europe Oncology NGS Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)
9.2.1 Academic Research
9.2.2 Clinical Research
9.2.3 Hospitals & Clinics
9.2.4 Pharma & Biotech Entities
9.2.5 Other users
9.3 Europe Oncology NGS Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)
9.3.1 Diagnostics and Screening
9.3.2 Screening
9.3.3 Sporadic Cancer
9.3.4 Inherited Cancer
9.3.5 Companion Diagnostics
9.3.6 Other Diagnostics
9.3.7 Research Studies
9.4 Europe Oncology NGS Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)
9.4.1 U.K.
9.4.2 Germany
9.4.3 France
9.4.4 Italy
9.4.5 Rest of Europe
9.5 Europe Oncology NGS Market Attractiveness Analysis
9.5.1 By Type
9.5.2 By Application
9.5.3 By Country
10 Asia Pacific Oncology NGS Market Analysis and Forecast
10.1 Key Findings
10.2 Asia Pacific Oncology NGS Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)
10.2.1 Academic Research
10.2.2 Clinical Research
10.2.3 Hospitals & Clinics
10.2.4 Pharma & Biotech Entities
10.2.5 Other users
10.3 Asia Pacific Oncology NGS Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)
10.3.1 Diagnostics and Screening
10.3.2 Screening
10.3.3 Sporadic Cancer
10.3.4 Inherited Cancer
10.3.5 Companion Diagnostics
10.3.6 Other Diagnostics
10.3.7 Research Studies
10.4 Asia Pacific Oncology NGS Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)
10.4.1 China
10.4.2 India
10.4.3 Japan
10.4.4 South Korea
10.4.5 Rest of APAC
10.5 Asia Pacific Oncology NGS Market Attractiveness Analysis
10.5.1 By Type
10.5.2 By Application
10.5.3 By Country
11 Latin America Oncology NGS Market Analysis and Forecast
11.1 Key Findings
11.2 Latin America Oncology NGS Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)
11.2.1 Academic Research
11.2.2 Clinical Research
11.2.3 Hospitals & Clinics
11.2.4 Pharma & Biotech Entities
11.2.5 Other users
11.3 Latin America Oncology NGS Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)
11.3.1 Diagnostics and Screening
11.3.2 Screening
11.3.3 Sporadic Cancer
11.3.4 Inherited Cancer
11.3.5 Companion Diagnostics
11.3.6 Other Diagnostics
11.3.7 Research Studies
11.4 Latin America Oncology NGS Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)
11.4.1 Brazil
11.4.2 Rest of Latin America China
11.5 Latin America Oncology NGS Market Attractiveness Analysis
11.5.1 By Type
11.5.2 By Application
11.5.3 By Country
12 Middle East & Africa (MEA) Oncology NGS Market Analysis and Forecast
12.1 Key Findings
12.2 Middle East & Africa (MEA) Oncology NGS Market Analysis (US$ Mn) and Forecast, By Product Type (2019-2028)
12.2.1 Academic Research
12.2.2 Clinical Research
12.2.3 Hospitals & Clinics
12.2.4 Pharma & Biotech Entities
12.2.5 Other users
12.3 Middle East & Africa (MEA) Oncology NGS Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)
12.3.1 Diagnostics and Screening
12.3.2 Screening
12.3.3 Sporadic Cancer
12.3.4 Inherited Cancer
12.3.5 Companion Diagnostics
12.3.6 Other Diagnostics
12.3.7 Research Studies
12.4 Middle East & Africa (MEA) Oncology NGS Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)
12.4.1 GCC Countries
12.4.2 South Africa
12.4.3 Rest of MEA
12.5 Middle East & Africa (MEA) Oncology NGS Market Attractiveness Analysis
12.5.1 By Type
12.5.2 By Application
12.5.3 By Country
13 Competitive Landscape
13.1 Market Players – Competition Matrix
13.2 Market Share Analysis by Key Players, 2020 (%)
13.3 Company Profiles
13.3.1 Illumina
13.3.1.1 Company Overview
13.3.1.2 Company Snapshot
13.3.1.3 Financial Overview
13.3.1.4 Product Portfolio
13.3.1.5 Key Developments/Strategies
13.3.2 Inc.
13.3.3 Genotypic Technology Pvt. Ltd.
13.3.4 Tecan Trading AG
13.3.5 SciGenom Labs Pvt. Ltd.
13.3.6 Xcelris Labs Ltd.
13.3.7 Eurofins Scientific
13.3.8 4baseCare
13.3.9 MedGenome
13.3.10 Sayre Therapeutics
13.3.11 Redcliffe Lifesciences
13.3.12 Partek Inc.
13.3.13 Bio-Rad Laboratories
13.3.14 Myriad Genetics
13.3.15 Hologic
13.3.16 Inc. (Gen-Probe Inc.)
13.3.17 Perkin Elmer
13.3.18 IncVela Diagnostics
13.3.19 Premas Life Sciences Pvt Ltd (PLS)
14 Key Takeaways
Choose License Type